Skip to search formSkip to main contentSkip to account menu

DBM-819

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

PyrrolesQuinolines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
General Pharmacological Properties of the New + /K + ATPase Inhibitor DBM-819
The effects of a newly synthesized ATPase inhibitor,1-(2-methyl-4-methoxypheny)-4-[(3-hy-droxypropyl)amino] -6-methyl-2,3… 
2002
2002
Determination of a new reversible proton pump inhibitor, DBM-819, in human plasma and urine, and rat tissue homogenates by high-performance liquid chromatography.
2001
2001
Pharmacological properties of a newly synthesized H+/K+ ATPase inhibitor, 1-(2-methyl-4-methoxyphenyl)-4-[(3-hydroxypropyl)amino]-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline
2001
2001
Pharmacological properties of a newly synthesized H(+)/K(+) ATPase inhibitor, 1-(2-methyl-4-methoxyphenyl)-4-.
2001
2001
In vitro metabolism of a new H(+)/K(+) ATPase inhibitor DBM-819 in liver microsomes using HPLC and electrospray mass spectrometry.
The metabolism of 1-(2-methyl-4-methoxyphenyl)-4-[(3-hydroxypropyl)amino]-6-methyl-2,3-dihydropyrrolo[3,2c]quinoline (DBM-819), a… 
2001
2001
Dose-dependent pharmacokinetics of a new reversible proton pump inhibitor, DBM-819, after intravenous and oral administration to rats: hepatic first-pass effect.
The dose-dependent pharmacokinetic parameters of DBM-819 were evaluated after intravenous (5, 10 and 20 mg/kg) and oral (10, 20… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)